Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

A. Bianco, A. K. Patanella, Viviana Nociti, Chiara De Fino, Matteo Lucchini, Francesco Lo Savio, Paolo Maria Rossini, Massimiliano Mirabella

Research output: Contribution to journalArticle

Abstract

In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.

Original languageEnglish
Pages (from-to)11-13
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Lung Volume Measurements
Dyspnea
Phase II Clinical Trials
Nose
Cough
Constriction
Therapeutics
Placebos
Pain
Incidence
Fingolimod Hydrochloride

Keywords

  • Adverse event
  • Fingolimod
  • Multiple sclerosis
  • Respiratory
  • Side effect

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. / Bianco, A.; Patanella, A. K.; Nociti, Viviana; De Fino, Chiara; Lucchini, Matteo; Savio, Francesco Lo; Rossini, Paolo Maria; Mirabella, Massimiliano.

In: Multiple Sclerosis and Related Disorders, Vol. 9, 01.09.2016, p. 11-13.

Research output: Contribution to journalArticle

Bianco, A. ; Patanella, A. K. ; Nociti, Viviana ; De Fino, Chiara ; Lucchini, Matteo ; Savio, Francesco Lo ; Rossini, Paolo Maria ; Mirabella, Massimiliano. / Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. In: Multiple Sclerosis and Related Disorders. 2016 ; Vol. 9. pp. 11-13.
@article{0d77e17c70dc4e50a599ff7eb47fb71c,
title = "Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment",
abstract = "In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.",
keywords = "Adverse event, Fingolimod, Multiple sclerosis, Respiratory, Side effect",
author = "A. Bianco and Patanella, {A. K.} and Viviana Nociti and {De Fino}, Chiara and Matteo Lucchini and Savio, {Francesco Lo} and Rossini, {Paolo Maria} and Massimiliano Mirabella",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.msard.2016.06.005",
language = "English",
volume = "9",
pages = "11--13",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

AU - Bianco, A.

AU - Patanella, A. K.

AU - Nociti, Viviana

AU - De Fino, Chiara

AU - Lucchini, Matteo

AU - Savio, Francesco Lo

AU - Rossini, Paolo Maria

AU - Mirabella, Massimiliano

PY - 2016/9/1

Y1 - 2016/9/1

N2 - In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.

AB - In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.

KW - Adverse event

KW - Fingolimod

KW - Multiple sclerosis

KW - Respiratory

KW - Side effect

UR - http://www.scopus.com/inward/record.url?scp=84974855179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974855179&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2016.06.005

DO - 10.1016/j.msard.2016.06.005

M3 - Article

VL - 9

SP - 11

EP - 13

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -